Every baby born in the United States has a thin ribbon of erythromycin antibiotic ointment applied to both eyes, usually within the first two hours of life. This is not a suggestion from your pediatrician or a hospital preference — in at least 32 states, it is required by law. The reason is a disease called gonococcal ophthalmia neonatorum, a severe eye infection that can cause permanent blindness within 24 hours of birth if a newborn is exposed to gonorrhea during vaginal delivery. Without prophylaxis, the transmission rate from an infected mother to her baby runs between 30 and 50 percent. The practice dates back to 1880, when a German obstetrician named Carl Credé introduced silver nitrate eye drops and watched the incidence of this blinding infection plummet from 13.6 percent to 0.05 percent in his Leipzig clinic. The original silver nitrate was eventually replaced — it caused chemical conjunctivitis in 50 to 90 percent of infants — but the principle of universal newborn eye prophylaxis became embedded in public health law across the Western world.
Today, erythromycin 0.5% ophthalmic ointment is the only FDA-approved agent for this purpose in the U.S. But this long-standing mandate is now facing scrutiny from multiple directions. A national erythromycin shortage has persisted since 2022. Major medical organizations are questioning whether universal mandates still make sense given modern prenatal screening. And in 2025, West Virginia became the first state in recent memory to repeal its century-old requirement. This article examines the history, the science, the legal landscape, and what these shifts could mean for families navigating the newborn period — a time already filled with enough decisions to overwhelm any parent, let alone one managing the cognitive demands of a caregiving role.
Table of Contents
- What Is the Antibiotic Applied to Newborns’ Eyes, and Why Is It Mandated by Law?
- The Disease Behind the Mandate — Ophthalmia Neonatorum and Its Consequences
- A State-by-State Patchwork — How Laws Differ Across the Country
- The Shifting Medical Consensus — From Universal Mandate to Targeted Approach
- The Erythromycin Shortage and the Problem of Having Only One Option
- West Virginia’s Repeal — A Signal of Things to Come?
- What This Debate Means for Families and Caregivers
- Conclusion
- Frequently Asked Questions
What Is the Antibiotic Applied to Newborns’ Eyes, and Why Is It Mandated by Law?
The antibiotic is erythromycin, specifically a 0.5% ophthalmic ointment. A nurse or midwife applies a thin line of the ointment into the lower conjunctival sac of each eye shortly after birth. It is a macrolide antibiotic — the same drug class sometimes prescribed for respiratory infections — and its purpose here is narrow and specific: to kill Neisseria gonorrhoeae bacteria that a baby may have picked up while passing through the birth canal. The procedure takes seconds. The ointment temporarily blurs the baby’s vision and can cause mild irritation, but these effects resolve quickly. The legal mandates exist because of what happens when prophylaxis is absent. Before Credé’s intervention in the 1880s, gonococcal ophthalmia neonatorum was the leading cause of permanent blindness in newborns. In Germany, more than 10 percent of all newborns developed the infection.
The bacteria attack the cornea aggressively — corneal scarring, ocular perforation, and total vision loss can occur within a single day. The infection can also seed into the bloodstream and cause meningitis, which is life-threatening. States began passing prophylaxis laws in the early twentieth century as a straightforward public health measure: the cost of a tube of ointment versus the cost of a blind child. Compare that history to where we are now. With universal prophylaxis in place, the U.S. rate of gonococcal ophthalmia neonatorum has fallen to approximately 0.4 cases per 100,000 live births per year, based on 2013–2017 data. That is a remarkable success — but it also creates a paradox familiar to anyone who has studied vaccine hesitancy. When a preventive measure works well enough, the disease it prevents becomes invisible, and people begin questioning whether the prevention is still necessary.
The Disease Behind the Mandate — Ophthalmia Neonatorum and Its Consequences
Ophthalmia neonatorum is not a single disease but a category — it refers to any conjunctivitis occurring in the first 28 days of life. The two infectious agents that matter most are Neisseria gonorrhoeae and Chlamydia trachomatis, both sexually transmitted bacteria that colonize the cervix. A baby’s eyes are exposed during passage through the birth canal, and the warm, moist environment of the conjunctiva is an ideal growth medium. Gonococcal ophthalmia is the more dangerous of the two. Symptoms typically appear within two to five days of birth: swelling, redness, and a thick purulent discharge. Left untreated, the bacteria can penetrate the cornea with frightening speed. The 24-hour window to permanent blindness is not an exaggeration — it is a clinical reality documented repeatedly in the medical literature. The infection can also disseminate, causing septic arthritis, meningitis, or sepsis. This is why laws single it out.
However, there is an important limitation to acknowledge: erythromycin prophylaxis is not effective against chlamydial conjunctivitis. Chlamydia is now the most common infectious cause of neonatal conjunctivitis in the U.S., responsible for 2 to 40 percent of cases, while gonorrhea causes less than 1 percent. Chlamydial conjunctivitis affects approximately 2 to 5 per 10,000 live births. So the ointment that is legally mandated addresses the rarer but more destructive pathogen while doing little for the more common one. This gap matters. If a mother has untreated chlamydia, her baby may develop conjunctivitis despite receiving erythromycin — and the parents may assume the prophylaxis failed or was unnecessary. In reality, the ointment was never designed to cover chlamydia. Prenatal screening and treatment of the mother remains the primary defense against chlamydial transmission. For families managing complex health situations — including those where a caregiver has cognitive impairment and may struggle to track follow-up appointments — understanding this distinction is critical. The ointment is a safety net, not a comprehensive shield.
A State-by-State Patchwork — How Laws Differ Across the Country
The legal landscape for newborn eye prophylaxis is not uniform. As of 2006, at least 32 U.S. states had laws on the books mandating the practice, and most continue to enforce them. But the specifics vary considerably. California’s Business and Professions Code §551 requires treatment of both eyes within two hours of birth. Washington state’s regulation WAC 246-100-202 similarly mandates erythromycin within two hours of delivery but includes a provision for parental refusal — if parents decline, the refusal must be documented. New York takes the hardest line: prophylaxis is mandatory without exception, and parents cannot legally refuse.
New York’s approach was tested during the erythromycin shortage. In January 2024, the state’s Department of Health issued guidance to hospitals navigating supply disruptions, and in April 2025 it reaffirmed its eye prophylaxis requirements. The message was clear — shortage or not, the mandate stands. Hospitals were expected to find the ointment, source alternatives, or work with state health authorities, but skipping the procedure was not an option. This patchwork creates confusion for families who move between states or deliver in a state different from where they received prenatal care. A mother in Washington who researches her right to refuse may be caught off guard if she delivers in New York. For older caregivers — grandparents raising grandchildren, for instance, a population that overlaps meaningfully with those at risk for cognitive decline — navigating these legal variations adds another layer of complexity to an already demanding process.
The Shifting Medical Consensus — From Universal Mandate to Targeted Approach
For decades, the medical establishment spoke with one voice on newborn eye prophylaxis: do it for every baby, no exceptions. That consensus is fracturing. In 2019, the U.S. Preventive Services Task Force reaffirmed its Grade A recommendation for prophylactic erythromycin ointment for all newborns, finding “convincing evidence” of effectiveness and no serious harms. A Grade A recommendation is the highest level — it means the USPSTF believes the benefit is substantial and the evidence is strong. But by 2024, the American Academy of Pediatrics had shifted.
The AAP now supports “ongoing re-evaluation of the medical necessity of legislative mandates” for universal prophylaxis. Instead of blanket treatment, the AAP recommends a more targeted approach: prenatal screening and treatment of gonorrhea and chlamydia, testing unscreened mothers at delivery, counseling parents to seek immediate care if their newborn develops signs of pink eye, and mandatory reporting of gonococcal ophthalmia neonatorum cases. In 2025, a joint statement from the American Academy of Ophthalmology, the AAP, and the American Association for Pediatric Ophthalmology and Strabismus acknowledged that “the necessity for mandatory eye prophylaxis has been questioned, primarily because rates of intrapartum exposure to gonorrhea have been greatly reduced by prenatal screening and treatment.” The tradeoff here is real. Universal prophylaxis is simple — every baby gets it, no one falls through the cracks, and you do not need to rely on the accuracy of prenatal records or the completeness of maternal screening. A targeted approach is more rational in theory but depends on a functioning healthcare infrastructure. If a mother did not receive prenatal care, if her screening results are not available at delivery, if there was a lab error — the baby is unprotected. For populations with limited healthcare access, including communities where dementia and other cognitive conditions reduce a family’s ability to manage complex medical records, the safety net of universal prophylaxis has real value.
The Erythromycin Shortage and the Problem of Having Only One Option
Since 2022, the United States has faced an ongoing national shortage of erythromycin ophthalmic ointment. Multiple manufacturers have ceased or reduced production, and the FDA has had to approve a Canadian-manufactured alternative to keep supply lines open. For a drug that is legally required in most states, a shortage is not merely inconvenient — it creates a genuine public health crisis where hospitals may be unable to comply with the law. The AAP issued guidance recommending ceftriaxone — a broad-spectrum injectable antibiotic given at 25 to 50 mg/kg intravenously or intramuscularly, with a maximum single dose of 250 mg — as an alternative for at-risk newborns during the shortage. Azithromycin ophthalmic solution at 1% concentration is another option under consideration, though it is more expensive and has not been formally proven effective for gonococcal ophthalmia neonatorum prevention.
Neither alternative is a true equivalent: ceftriaxone requires an injection rather than a simple eye application, and azithromycin lacks the regulatory approval that erythromycin carries. This shortage exposes a deeper vulnerability. The United States has exactly one FDA-approved prophylactic agent for a legally mandated procedure, and when supply fails, there is no seamless backup. For hospital pharmacists, this means scrambling. For parents, it may mean their baby receives a different treatment than expected — or, in worst-case scenarios, no prophylaxis at all. The situation is a cautionary example of what happens when a public health system builds legal requirements around a single product without ensuring supply chain resilience.
West Virginia’s Repeal — A Signal of Things to Come?
In 2025, West Virginia became a test case for the deregulation of newborn eye prophylaxis. House Bill 3444, sponsored by Delegate Evan Worrell, a Republican from Cabell County, repealed the state’s mandate that had been in place for more than a century. The bill went into effect in July 2025 without Governor Patrick Morrisey’s signature — he neither signed nor vetoed it, letting it become law by default. Importantly, the bill does not ban erythromycin prophylaxis.
It removes the legal obligation, leaving the decision to parents and providers. The national nonprofit Prevent Blindness publicly opposed the bill, warning it would “imperil children’s vision.” The concern is not hypothetical. While gonorrhea rates are low nationally, they are not zero, and they have been rising in recent years. Removing the mandate does not eliminate the disease — it eliminates the guarantee that every baby is protected. Whether other states follow West Virginia’s lead will likely depend on how medical organizations continue to evolve their recommendations and whether any cases of preventable blindness emerge in states that relax their requirements.
What This Debate Means for Families and Caregivers
The newborn eye prophylaxis debate sits at the intersection of individual autonomy and collective protection — a tension that runs through nearly every public health mandate. For families where a grandparent or older relative is the primary caregiver, and where that caregiver may be experiencing early cognitive changes, the simplicity of a universal mandate has practical value. There is no decision to research, no form to sign, no risk of a missed step. The baby gets the ointment, and one potential catastrophe is taken off the table.
As medical organizations move toward targeted approaches, the burden of informed decision-making shifts to families and frontline providers. This is appropriate when the infrastructure supports it — when prenatal screening is reliable, when results are communicated clearly, when parents have the cognitive bandwidth to evaluate risks. But it is worth asking who falls through the gaps when universal protections are removed. The answer, historically, is the most vulnerable: those without consistent prenatal care, those whose medical records are incomplete, and those whose family support systems are already strained. Whatever direction this debate takes, the underlying principle remains unchanged — a newborn’s eyesight is not something to gamble with.
Conclusion
Erythromycin eye ointment for newborns is one of the oldest and most successful public health interventions in modern medicine. From Carl Credé’s silver nitrate drops in 1880 to today’s legal mandates across most U.S. states, the practice has reduced gonococcal ophthalmia neonatorum from a leading cause of childhood blindness to a condition that occurs in fewer than one in 200,000 births. The ointment is safe, fast to apply, and addresses a disease that can destroy a newborn’s vision in less than a day.
But the landscape is changing. The erythromycin shortage, the shift in AAP recommendations, and West Virginia’s repeal of its mandate all point toward a future where universal prophylaxis may give way to a more targeted model. For families — especially those where caregivers are managing their own health challenges, including cognitive decline — staying informed about these changes matters. Whether your state requires the ointment or leaves it to parental choice, understanding what it does, what it does not do, and why it exists is the foundation for making sound decisions during one of life’s most consequential moments.
Frequently Asked Questions
What exactly is erythromycin eye ointment, and how is it applied to newborns?
Erythromycin 0.5% ophthalmic ointment is the only FDA-approved antibiotic for preventing gonococcal eye infections in newborns. A nurse applies a thin ribbon of the ointment into both of the baby’s eyes, typically within one to two hours of birth. It temporarily blurs the baby’s vision and may cause mild irritation, but these effects resolve quickly.
Can parents refuse the eye ointment for their newborn?
It depends on the state. Some states, like Washington, allow parents to refuse but require that the refusal be documented. New York does not permit refusal under any circumstances. As of 2025, West Virginia removed its mandate entirely, making it optional. Parents should check their state’s specific laws before delivery.
Does the eye ointment protect against chlamydia?
No. Erythromycin prophylaxis targets Neisseria gonorrhoeae specifically and is not effective against Chlamydia trachomatis, which is now the most common infectious cause of neonatal conjunctivitis. Prenatal screening and treatment of the mother is the primary defense against chlamydial transmission to the newborn.
What happens if the hospital does not have erythromycin due to the shortage?
During the ongoing shortage, the AAP has recommended ceftriaxone, an injectable antibiotic, as an alternative for at-risk newborns. Azithromycin ophthalmic solution is also under consideration. The FDA has approved a Canadian-manufactured erythromycin product to help address supply gaps.
If gonorrhea rates in newborns are so low, why is the ointment still required?
The rates are low precisely because prophylaxis is in place. Without it, the 30 to 50 percent transmission rate from infected mothers would lead to significantly more cases. Medical organizations are debating whether targeted screening can replace universal treatment, but no state besides West Virginia has repealed its mandate as of 2025.
Is there any connection between newborn eye infections and long-term neurological health?
Gonococcal ophthalmia neonatorum can lead to disseminated gonococcal infection, including meningitis, which is an infection of the membranes surrounding the brain and spinal cord. Neonatal meningitis carries risks of long-term neurological consequences. While this outcome is rare with prophylaxis in place, it underscores why prevention is taken seriously.
